Shares of Pulmonx Co. (NASDAQ:LUNG) have been given a consensus rating of "Buy" by the nine ratings firms that are presently covering the firm, MarketBeat.com reports. Three analysts have rated the stock with a hold recommendation and five have given a buy recommendation to the company. The average 12-month price target among brokers that have issued ratings on the stock in the last year is $58.00.
LUNG has been the subject of a number of research reports. Zacks Investment Research upgraded Pulmonx from a "sell" rating to a "hold" rating in a report on Wednesday, May 5th. initiated coverage on shares of Pulmonx in a research note on Thursday, April 1st. They set a "buy" rating and a $60.00 price objective for the company. Finally, Citigroup initiated coverage on shares of Pulmonx in a research note on Thursday, April 1st. They set a "buy" rating and a $60.00 price objective for the company.
In other Pulmonx news, CEO Glendon E. French III sold 25,000 shares of the firm's stock in a transaction that occurred on Thursday, May 20th. The shares were sold at an average price of $41.95, for a total transaction of $1,048,750.00. Following the completion of the sale, the chief executive officer now directly owns 1,219,825 shares in the company, valued at $51,171,658.75. The sale was disclosed in a document filed with the Securities & Exchange Commission, which is available at this hyperlink. Also, insider Geoffrey Beran Rose sold 4,797 shares of the firm's stock in a transaction that occurred on Monday, May 10th. The stock was sold at an average price of $40.70, for a total transaction of $195,237.90. Following the sale, the insider now owns 117,692 shares of the company's stock, valued at $4,790,064.40. The disclosure for this sale can be found here. Insiders sold a total of 2,591,594 shares of company stock valued at $97,378,449 over the last quarter. 12.56% of the stock is currently owned by company insiders.
A number of hedge funds have recently modified their holdings of the business. Greenspring Associates LLC bought a new position in shares of Pulmonx during the first quarter worth approximately $26,000. Royal Bank of Canada increased its holdings in shares of Pulmonx by 119.0% during the first quarter. Royal Bank of Canada now owns 863 shares of the company's stock worth $40,000 after purchasing an additional 469 shares during the period. Citigroup Inc. bought a new position in shares of Pulmonx during the fourth quarter worth approximately $151,000. Dynamic Technology Lab Private Ltd bought a new position in shares of Pulmonx during the first quarter worth approximately $207,000. Finally, UBS Group AG increased its holdings in shares of Pulmonx by 118.1% during the first quarter. UBS Group AG now owns 4,534 shares of the company's stock worth $207,000 after purchasing an additional 2,455 shares during the period. Hedge funds and other institutional investors own 59.59% of the company's stock.
LUNG stock opened at $40.20 on Friday. The business's 50-day moving average price is $42.16. The company has a market cap of $1.46 billion and a PE ratio of -12.72. The company has a debt-to-equity ratio of 0.08, a quick ratio of 16.22 and a current ratio of 17.07. Pulmonx has a 1 year low of $35.81 and a 1 year high of $69.48.
Pulmonx (NASDAQ:LUNG) last released its earnings results on Monday, May 3rd. The company reported ($0.34) earnings per share (EPS) for the quarter, topping the Zacks' consensus estimate of ($0.39) by $0.05. The firm had revenue of $9.24 million for the quarter, compared to the consensus estimate of $8.18 million. On average, equities analysts expect that Pulmonx will post -1.47 earnings per share for the current year.
Pulmonx Corporation, a medical technology company, designs, develops, manufactures, and markets minimally invasive medical devices for the diagnosis and treatment of chronic obstructive pulmonary diseases. It offers Zephyr Endobronchial Valve, a solution for the treatment of bronchoscopic in adult patients with hyperinflation associated with severe emphysema; and Chartis Pulmonary Assessment System, a balloon catheter and console with flow and pressure sensors that are used to assess the presence of collateral ventilation.
Featured Article: What is the S&P/ASX 200 Index?
This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest and most accurate reporting. This story was reviewed by MarketBeat's editorial team prior to publication. Please send any questions or comments about this story to [email protected]
Before you consider Pulmonx, you'll want to hear this.
MarketBeat keeps track of Wall Street's top-rated and best performing research analysts and the stocks they recommend to their clients on a daily basis. MarketBeat has identified the five stocks that top analysts are quietly whispering to their clients to buy now before the broader market catches on... and Pulmonx wasn't on the list.
While Pulmonx currently has a "Buy" rating among analysts, top-rated analysts believe these five stocks are better buys.
View The 5 Stocks Here